文献速递炎症性肠病

当完美成为优秀的敌人:无症状炎症性肠病达标治疗RAND适宜性专家组结果

When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2024-07-15

采用RAND/加州大学洛杉矶分校适宜性方法,9名炎症性肠病专家对126个无症状但内镜活动期溃疡性结肠炎和克罗恩病场景进行改变治疗的适宜性评分。96/126个场景评为适宜,27个评为不确定,部分场景评为不适宜;未跨越分歧阈值。

要点

  • 无症状IBD内镜活动期改变治疗适宜性因疾病进展、复杂程度和范围而异
  • 轻度稳定病变或既往暴露≥3种治疗者改变治疗评为不适宜
  • 年龄>65岁和计划一年内妊娠可能影响部分场景决策

核心结论

  • 适宜性评分可帮助指导无症状IBD患者改变治疗以实现内镜缓解的临床决策,直至正在进行的随机研究数据可用。

研究设计与样本

  • 采用RAND/加州大学洛杉矶分校适宜性方法,9名IBD专家对126个无症状溃疡性结肠炎和克罗恩病伴活动性内镜疾病场景进行适宜性评分。
  • 考虑疾病范围和行为、既往治疗、既往并发症、近期疾病进展以及年龄和妊娠等因素。
  • 通过匿名调查收集评分,面对面会议讨论,第二次匿名调查最终确定。

主要发现

  • 专家组在96/126个场景中评为改变治疗适宜,通常为进展性、复杂性和/或广泛性疾病患者。
  • 在27个轻度和/或稳定性疾病场景中改变治疗评为不确定。
  • 在既往暴露≥3种治疗或内镜活动改善的轻度稳定溃疡性结肠炎患者以及仅有散在阿弗他溃疡的克罗恩病患者中,改变治疗评为不适宜。
  • 任何场景均未跨越已验证的分歧阈值。
  • 患者年龄大于65岁和计划一年内妊娠可能在某些情况下影响决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A treat-to-target strategy for inflammatory bowel disease (IBD) recommends iterative treatment adjustments to achieve clinical and endoscopic remission. In asymptomatic patients with ongoing endoscopic activity, the risk/benefit balance of this approach is unclear, particularly with prior exposure to advanced therapies. METHODS: Using the RAND/University of California Los Angeles Appropriateness Method, 9 IBD specialists rated appropriateness of changing therapy in 126 scenarios of asymptomatic patients with ulcerative colitis and Crohn's disease and active endoscopic disease. Disease extent and behavior, prior treatment, prior complications, and recent disease progression were considered, as were factors that might influence decision-making, including age and pregnancy. Ratings were collected through anonymous survey, discussed at an in-person meeting, and finalized in a second anonymous survey. RESULTS: Panelists rated change in therapy as appropriate (i.e., expected benefit sufficiently outweighs potential harms from continuing therapy) in 96/126 scenarios, generally in patients with progressive, complicated, and/or extensive disease, while changing therapy was rated uncertain in 27 scenarios of mild and/or stable disease. Changing therapy was rated inappropriate in ulcerative colitis patients with mild and stable disease previously exposed to ≥3 therapies or with improved endoscopic activity, and in Crohn's disease patients with only scattered aphthous ulcers. The validated threshold for disagreement was not crossed for any scenario. Patient age older than 65 years and a plan for pregnancy in the next year might influence decision-making in some settings. DISCUSSION: Appropriateness ratings can help guide clinical decision-making about changing therapy to achieve endoscopic remission in asymptomatic patients with IBD until data from ongoing randomized studies are available.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Systrom HK, Rai V, Singh S, et al. When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease. Am J Gastroenterol. 2024. PMID: 39008539. doi:10.14309/ajg.0000000000002964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。